The abstract is read at the publisher; the summary is JClub's.
CYB2-knockout Saccharomyces cerevisiae shows potent antibacterial activity in mouse urinary tract infection and enteritis models, improving survival and lowering bacterial counts.
- Why it matters: Antibiotic resistance limits treatment of bacterial infections, and probiotic mechanisms are still unclear, especially how engineered yeast strains inhibit pathogens in vivo.
- What they did: From 1,733 strains in the homozygous diploid YKOC, CYB2-KO was identified; it inhibited multidrug-resistant bacteria, reduced biofilms, and increased cell wall/membrane permeability, while lactic acid (LA) accumulation was tested via exogenous LA, pH neutralization, and LA-supplemented BY4743 CFS.
- The result: LA accumulation and environmental acidification are linked to antibacterial effects, and LA is shown as the key effector metabolite, enabling CYB2-KO yeast to enhance survival and reduce bladder, ileum, colon, and cecum bacterial loads.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.